CBT-502 (Programmable Death Ligand-1)

  • A novel IgG1 humanized monoclonal antibody against the Programmable Death Ligand-1 (PDL-1) membrane receptor on tumor cells.
  • An Investigational Drug Application in China has been approved and a Phase 1 trial is planned to be initiated by Chia Tai TianQing (CTTQ).
  • CBT Pharmaceuticals retains with worldwide rights while in China, rights were granted to CTTQ.